25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Novo Nordisk A/S
Buy, Hold or Sell?

Let's analyze Novo Nordisk A/S together

I guess you are interested in Novo Nordisk A/S. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Novo Nordisk A/S. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Novo Nordisk A/S

I send you an email if I find something interesting about Novo Nordisk A/S.

1. Quick Overview

1.1. Quick analysis of Novo Nordisk A/S (30 sec.)










1.2. What can you expect buying and holding a share of Novo Nordisk A/S? (30 sec.)

How much money do you get?

How much money do you get?
€1.44
When do you have the money?
1 year
How often do you get paid?
50.0%

What is your share worth?

Current worth
€4.33
Expected worth in 1 year
€5.46
How sure are you?
92.9%

+ What do you gain per year?

Total Gains per Share
€2.45
Return On Investment
3.4%

For what price can you sell your share?

Current Price per Share
€72.40
Expected price per share
€70.00 - €92.89
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Novo Nordisk A/S (5 min.)




Live pricePrice per Share (EOD)
€72.40
Intrinsic Value Per Share
€28.37 - €33.01
Total Value Per Share
€32.69 - €37.34

2.2. Growth of Novo Nordisk A/S (5 min.)




Is Novo Nordisk A/S growing?

Current yearPrevious yearGrowGrow %
How rich?$20.8b$13.4b$3.8b22.2%

How much money is Novo Nordisk A/S making?

Current yearPrevious yearGrowGrow %
Making money$3.6b$3b$629.1m17.1%
Net Profit Margin34.9%36.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Novo Nordisk A/S (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Novo Nordisk A/S?

Welcome investor! Novo Nordisk A/S's management wants to use your money to grow the business. In return you get a share of Novo Nordisk A/S.

First you should know what it really means to hold a share of Novo Nordisk A/S. And how you can make/lose money.

Speculation

The Price per Share of Novo Nordisk A/S is €72.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Novo Nordisk A/S.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Novo Nordisk A/S, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €4.33. Based on the TTM, the Book Value Change Per Share is €0.28 per quarter. Based on the YOY, the Book Value Change Per Share is €0.18 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.33 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Novo Nordisk A/S.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.921.3%0.821.1%0.680.9%0.761.0%0.761.0%
Usd Book Value Change Per Share0.761.1%0.310.4%0.190.3%0.340.5%0.340.5%
Usd Dividend Per Share0.000.0%0.360.5%0.260.4%0.330.5%0.330.5%
Usd Total Gains Per Share0.761.1%0.670.9%0.450.6%0.660.9%0.660.9%
Usd Price Per Share90.72-120.62-128.95-119.26-119.26-
Price to Earnings Ratio24.54-38.01-48.39-41.88-41.88-
Price-to-Total Gains Ratio119.30-196.31-298.26-204.06-204.06-
Price to Book Ratio19.31-32.19-44.21-33.90-33.90-
Price-to-Total Gains Ratio119.30-196.31-298.26-204.06-204.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share78.56848
Number of shares12
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.360.33
Usd Book Value Change Per Share0.310.34
Usd Total Gains Per Share0.670.66
Gains per Quarter (12 shares)7.997.97
Gains per Year (12 shares)31.9431.88
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1171522161622
2352954323254
3524486474886
469591186364118
586731507981150
6104881829597182
7121103214110113214
8138117246126129246
9155132278142145278
10173147310158161310

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%14.00.00.0100.0%14.00.00.0100.0%14.00.00.0100.0%
Book Value Change Per Share3.01.00.075.0%8.04.00.066.7%10.04.00.071.4%10.04.00.071.4%10.04.00.071.4%
Dividend per Share2.00.02.050.0%6.00.06.050.0%7.00.07.050.0%7.00.07.050.0%7.00.07.050.0%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%13.01.00.092.9%13.01.00.092.9%13.01.00.092.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Novo Nordisk A/S compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.7010.282+149%0.179+291%0.309+127%0.309+127%
Book Value Per Share--4.3293.578+21%2.768+56%3.480+24%3.480+24%
Current Ratio--0.7400.831-11%0.847-13%0.876-16%0.876-16%
Debt To Asset Ratio--0.6920.688+1%0.677+2%0.670+3%0.670+3%
Debt To Equity Ratio--2.2462.212+2%2.103+7%2.043+10%2.043+10%
Dividend Per Share---0.332-100%0.237-100%0.303-100%0.303-100%
Enterprise Value--328106657124.800459560186768.950-29%506416439418.400-35%388869161387.186-16%388869161387.186-16%
Eps--0.8520.760+12%0.626+36%0.698+22%0.698+22%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--7.14412.143-41%16.675-57%13.151-46%13.151-46%
Free Cash Flow Per Share---0.1280.524-125%0.523-125%0.629-120%0.629-120%
Free Cash Flow To Equity Per Share--0.9830.591+66%0.051+1842%0.280+251%0.280+251%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--33.012--------
Intrinsic Value_10Y_min--28.366--------
Intrinsic Value_1Y_max--2.750--------
Intrinsic Value_1Y_min--2.701--------
Intrinsic Value_3Y_max--8.688--------
Intrinsic Value_3Y_min--8.285--------
Intrinsic Value_5Y_max--15.138--------
Intrinsic Value_5Y_min--14.015--------
Market Cap--371296063124.800494939503268.950-25%532394550418.400-30%414351060815.757-10%414351060815.757-10%
Net Profit Margin--0.3290.349-6%0.361-9%0.337-2%0.337-2%
Operating Margin----0%-0%-0%-0%
Operating Ratio--0.7230.710+2%0.711+2%0.7270%0.7270%
Pb Ratio16.724-15%19.31132.192-40%44.205-56%33.903-43%33.903-43%
Pe Ratio21.251-15%24.53838.008-35%48.390-49%41.875-41%41.875-41%
Price Per Share72.400-15%83.600111.150-25%118.825-30%109.893-24%109.893-24%
Price To Free Cash Flow Ratio-140.924+13%-162.72420.777-883%4.524-3697%89.297-282%89.297-282%
Price To Total Gains Ratio103.319-15%119.302196.310-39%298.259-60%204.058-42%204.058-42%
Quick Ratio--0.3800.384-1%0.462-18%0.435-13%0.435-13%
Return On Assets--0.0610.067-10%0.073-17%0.067-9%0.067-9%
Return On Equity--0.1970.215-8%0.228-14%0.204-3%0.204-3%
Total Gains Per Share--0.7010.613+14%0.416+68%0.612+14%0.612+14%
Usd Book Value--20865274964.80017284277202.200+21%13447382225.800+55%13330212639.200+57%13330212639.200+57%
Usd Book Value Change Per Share--0.7600.306+149%0.194+291%0.336+127%0.336+127%
Usd Book Value Per Share--4.6983.883+21%3.004+56%3.777+24%3.777+24%
Usd Dividend Per Share---0.360-100%0.257-100%0.329-100%0.329-100%
Usd Enterprise Value--356061344311.833498714714681.665-29%549563120056.848-35%422000813937.374-16%422000813937.374-16%
Usd Eps--0.9240.825+12%0.680+36%0.757+22%0.757+22%
Usd Free Cash Flow---619039317.6002532397217.800-124%2545230250.400-124%2267390680.171-127%2267390680.171-127%
Usd Free Cash Flow Per Share---0.1390.569-125%0.567-125%0.682-120%0.682-120%
Usd Free Cash Flow To Equity Per Share--1.0670.641+66%0.055+1842%0.304+251%0.304+251%
Usd Market Cap--402930487703.033537108348947.465-25%577754566114.048-30%449653771197.260-10%449653771197.260-10%
Usd Price Per Share78.568-15%90.723120.620-25%128.949-30%119.256-24%119.256-24%
Usd Profit--4105116264.0003671337949.600+12%3042228518.600+35%2733908548.400+50%2733908548.400+50%
Usd Revenue--12459747674.40010557368742.600+18%8443662846.200+48%8035036444.743+55%8035036444.743+55%
Usd Total Gains Per Share--0.7600.666+14%0.452+68%0.664+14%0.664+14%
 EOD+3 -3MRQTTM+17 -20YOY+17 -205Y+18 -1910Y+18 -19

3.3 Fundamental Score

Let's check the fundamental score of Novo Nordisk A/S based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1521.251
Price to Book Ratio (EOD)Between0-116.724
Net Profit Margin (MRQ)Greater than00.329
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.380
Current Ratio (MRQ)Greater than10.740
Debt to Asset Ratio (MRQ)Less than10.692
Debt to Equity Ratio (MRQ)Less than12.246
Return on Equity (MRQ)Greater than0.150.197
Return on Assets (MRQ)Greater than0.050.061
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Novo Nordisk A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose80.400
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Novo Nordisk A/S

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Novo Nordisk A/S earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Net Profit Margin of 32.9% means that €0.33 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novo Nordisk A/S:

  • The MRQ is 32.9%. The company is making a huge profit. +2
  • The TTM is 34.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ32.9%TTM34.9%-1.9%
TTM34.9%YOY36.1%-1.2%
TTM34.9%5Y33.7%+1.1%
5Y33.7%10Y33.7%0.0%
4.3.1.2. Return on Assets

Shows how efficient Novo Nordisk A/S is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • 6.1% Return on Assets means that Novo Nordisk A/S generated €0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novo Nordisk A/S:

  • The MRQ is 6.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 6.7%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ6.1%TTM6.7%-0.7%
TTM6.7%YOY7.3%-0.6%
TTM6.7%5Y6.7%+0.0%
5Y6.7%10Y6.7%0.0%
4.3.1.3. Return on Equity

Shows how efficient Novo Nordisk A/S is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • 19.7% Return on Equity means Novo Nordisk A/S generated €0.20 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novo Nordisk A/S:

  • The MRQ is 19.7%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 21.5%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ19.7%TTM21.5%-1.8%
TTM21.5%YOY22.8%-1.3%
TTM21.5%5Y20.4%+1.1%
5Y20.4%10Y20.4%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Novo Nordisk A/S.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Novo Nordisk A/S is operating .

  • Measures how much profit Novo Nordisk A/S makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novo Nordisk A/S:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Novo Nordisk A/S is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.72 means that the operating costs are €0.72 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.723. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.710. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.723TTM0.710+0.013
TTM0.710YOY0.7110.000
TTM0.7105Y0.727-0.016
5Y0.72710Y0.7270.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Novo Nordisk A/S.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 0.74 means the company has €0.74 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.740. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.831. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.740TTM0.831-0.091
TTM0.831YOY0.847-0.016
TTM0.8315Y0.876-0.045
5Y0.87610Y0.8760.000
4.4.3.2. Quick Ratio

Measures if Novo Nordisk A/S is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Quick Ratio of 0.38 means the company can pay off €0.38 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.380. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.384. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.380TTM0.384-0.004
TTM0.384YOY0.462-0.078
TTM0.3845Y0.435-0.051
5Y0.43510Y0.4350.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Novo Nordisk A/S.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Novo Nordisk A/S assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novo Nordisk A/S to industry mean.
  • A Debt to Asset Ratio of 0.69 means that Novo Nordisk A/S assets are financed with 69.2% credit (debt) and the remaining percentage (100% - 69.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novo Nordisk A/S:

  • The MRQ is 0.692. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.688. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.692TTM0.688+0.004
TTM0.688YOY0.677+0.011
TTM0.6885Y0.670+0.018
5Y0.67010Y0.6700.000
4.5.4.2. Debt to Equity Ratio

Measures if Novo Nordisk A/S is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novo Nordisk A/S to the  industry mean.
  • A Debt to Equity ratio of 224.6% means that company has €2.25 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novo Nordisk A/S:

  • The MRQ is 2.246. The company is just not able to pay all its debts with equity.
  • The TTM is 2.212. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.246TTM2.212+0.034
TTM2.212YOY2.103+0.109
TTM2.2125Y2.043+0.169
5Y2.04310Y2.0430.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Novo Nordisk A/S generates.

  • Above 15 is considered overpriced but always compare Novo Nordisk A/S to the  industry mean.
  • A PE ratio of 24.54 means the investor is paying €24.54 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novo Nordisk A/S:

  • The EOD is 21.251. Based on the earnings, the company is fair priced.
  • The MRQ is 24.538. Based on the earnings, the company is fair priced.
  • The TTM is 38.008. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD21.251MRQ24.538-3.287
MRQ24.538TTM38.008-13.469
TTM38.008YOY48.390-10.382
TTM38.0085Y41.875-3.868
5Y41.87510Y41.8750.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Novo Nordisk A/S:

  • The EOD is -140.924. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -162.724. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 20.777. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD-140.924MRQ-162.724+21.800
MRQ-162.724TTM20.777-183.501
TTM20.777YOY4.524+16.253
TTM20.7775Y89.297-68.520
5Y89.29710Y89.2970.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Novo Nordisk A/S is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 19.31 means the investor is paying €19.31 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Novo Nordisk A/S:

  • The EOD is 16.724. Based on the equity, the company is expensive. -2
  • The MRQ is 19.311. Based on the equity, the company is expensive. -2
  • The TTM is 32.192. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD16.724MRQ19.311-2.587
MRQ19.311TTM32.192-12.881
TTM32.192YOY44.205-12.014
TTM32.1925Y33.903-1.711
5Y33.90310Y33.9030.000
4.6.2. Total Gains per Share

2.4. Latest News of Novo Nordisk A/S

Does Novo Nordisk A/S still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Novo Nordisk A/S to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-02-21
22:33
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs ShortageRead
2025-02-21
18:39
CrowdStrike, Hims & Hers, Rivian: Market MinuteRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Reconciled Depreciation  400,928-10,452390,476794,7541,185,230-897,130288,100-1,006,876-718,776



6.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in DKK. All numbers in thousands.

Summary
Total Assets465,795,000
Total Liabilities322,309,000
Total Stockholder Equity143,486,000
 As reported
Total Liabilities 322,309,000
Total Stockholder Equity+ 143,486,000
Total Assets = 465,795,000

Assets

Total Assets465,795,000
Total Current Assets160,897,000
Long-term Assets304,898,000
Total Current Assets
Cash And Cash Equivalents 15,655,000
Short-term Investments 10,653,000
Net Receivables 71,949,000
Inventory 40,849,000
Total Current Assets  (as reported)160,897,000
Total Current Assets  (calculated)139,106,000
+/- 21,791,000
Long-term Assets
Property Plant Equipment 162,488,000
Goodwill 20,064,000
Long Term Investments 2,677,000
Intangible Assets 91,026,000
Long-term Assets  (as reported)304,898,000
Long-term Assets  (calculated)276,255,000
+/- 28,643,000

Liabilities & Shareholders' Equity

Total Current Liabilities217,528,000
Long-term Liabilities104,781,000
Total Stockholder Equity143,486,000
Total Current Liabilities
Short Long Term Debt 11,775,000
Accounts payable 28,846,000
Other Current Liabilities 45,524,000
Total Current Liabilities  (as reported)217,528,000
Total Current Liabilities  (calculated)86,145,000
+/- 131,383,000
Long-term Liabilities
Long term Debt 84,246,000
Capital Lease Obligations Min Short Term Debt6,766,000
Long-term Liabilities Other 23,000
Long-term Liabilities  (as reported)104,781,000
Long-term Liabilities  (calculated)91,035,000
+/- 13,746,000
Total Stockholder Equity
Retained Earnings 144,448,000
Total Stockholder Equity (as reported)143,486,000
Total Stockholder Equity (calculated)144,448,000
+/- 962,000
Other
Capital Stock446,000
Common Stock Shares Outstanding 4,441,340
Net Debt 80,366,000
Net Invested Capital 239,507,000
Net Working Capital -56,631,000
Property Plant and Equipment Gross 214,884,000



6.3. Balance Sheets Structured

Currency in DKK. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
174,084,000
194,508,000
197,136,000
218,928,000
242,836,000
241,257,000
250,025,000
280,753,000
300,101,000
314,486,000
298,921,000
369,383,000
397,441,000
465,795,000
465,795,000397,441,000369,383,000298,921,000314,486,000300,101,000280,753,000250,025,000241,257,000242,836,000218,928,000197,136,000194,508,000174,084,000
   > Total Current Assets 
91,213,000
85,595,000
86,537,000
102,979,000
119,482,000
108,194,000
113,943,000
137,551,000
142,199,000
139,646,000
116,421,000
177,500,000
195,160,000
160,897,000
160,897,000195,160,000177,500,000116,421,000139,646,000142,199,000137,551,000113,943,000108,194,000119,482,000102,979,00086,537,00085,595,00091,213,000
       Cash And Cash Equivalents 
29,493,000
10,720,000
13,394,000
22,758,000
28,465,000
12,653,000
14,936,000
21,574,000
30,144,000
14,392,000
6,324,000
52,821,000
57,018,000
15,655,000
15,655,00057,018,00052,821,0006,324,00014,392,00030,144,00021,574,00014,936,00012,653,00028,465,00022,758,00013,394,00010,720,00029,493,000
       Short-term Investments 
5,897,000
6,765,000
6,752,000
8,279,000
9,008,000
10,921,000
12,835,000
14,834,000
17,451,000
15,838,000
2,979,000
9,833,000
17,863,000
10,653,000
10,653,00017,863,0009,833,0002,979,00015,838,00017,451,00014,834,00012,835,00010,921,0009,008,0008,279,0006,752,0006,765,0005,897,000
       Net Receivables 
29,860,000
40,643,000
36,241,000
40,826,000
45,563,000
50,560,000
50,502,000
61,294,000
52,602,000
64,770,000
56,999,000
63,565,000
66,299,000
71,949,000
71,949,00066,299,00063,565,00056,999,00064,770,00052,602,00061,294,00050,502,00050,560,00045,563,00040,826,00036,241,00040,643,00029,860,000
       Inventory 
18,899,000
19,621,000
20,289,000
21,706,000
23,222,000
24,388,000
25,615,000
28,020,000
29,534,000
31,811,000
33,600,000
36,356,000
37,944,000
40,849,000
40,849,00037,944,00036,356,00033,600,00031,811,00029,534,00028,020,00025,615,00024,388,00023,222,00021,706,00020,289,00019,621,00018,899,000
   > Long-term Assets 
82,871,000
108,913,000
110,599,000
115,949,000
123,354,000
133,063,000
136,082,000
143,202,000
157,902,000
174,840,000
182,500,000
191,883,000
202,281,000
304,898,000
304,898,000202,281,000191,883,000182,500,000174,840,000157,902,000143,202,000136,082,000133,063,000123,354,000115,949,000110,599,000108,913,00082,871,000
       Property Plant Equipment 
0
0
0
0
63,641,000
66,671,000
70,014,000
75,024,000
81,461,000
90,961,000
98,230,000
109,980,000
119,832,000
162,488,000
162,488,000119,832,000109,980,00098,230,00090,961,00081,461,00075,024,00070,014,00066,671,00063,641,0000000
       Goodwill 
0
4,346,000
0
0
0
4,615,000
0
0
0
4,464,000
0
0
0
20,064,000
20,064,0000004,464,0000004,615,0000004,346,0000
       Long Term Investments 
1,778,000
1,441,000
1,279,000
1,242,000
1,239,000
1,343,000
1,211,000
1,479,000
1,471,000
1,663,000
1,651,000
1,659,000
2,047,000
2,677,000
2,677,0002,047,0001,659,0001,651,0001,663,0001,471,0001,479,0001,211,0001,343,0001,239,0001,242,0001,279,0001,441,0001,778,000
       Intangible Assets 
0
38,825,000
0
0
0
46,324,000
0
0
0
55,942,000
0
0
0
91,026,000
91,026,00000055,942,00000046,324,00000038,825,0000
> Total Liabilities 
107,972,000
123,762,000
130,586,000
144,476,000
166,156,000
157,771,000
170,151,000
190,280,000
207,110,000
207,925,000
200,010,000
256,861,000
276,919,000
322,309,000
322,309,000276,919,000256,861,000200,010,000207,925,000207,110,000190,280,000170,151,000157,771,000166,156,000144,476,000130,586,000123,762,000107,972,000
   > Total Current Liabilities 
88,328,000
99,516,000
95,602,000
109,655,000
130,257,000
120,940,000
131,961,000
156,618,000
172,552,000
169,655,000
165,606,000
187,909,000
208,358,000
217,528,000
217,528,000208,358,000187,909,000165,606,000169,655,000172,552,000156,618,000131,961,000120,940,000130,257,000109,655,00095,602,00099,516,00088,328,000
       Short Long Term Debt 
1,350,000
12,862,000
1,396,000
1,256,000
1,833,000
480,000
1,251,000
6,289,000
6,613,000
5,304,000
10,164,000
5,452,000
5,520,000
11,775,000
11,775,0005,520,0005,452,00010,164,0005,304,0006,613,0006,289,0001,251,000480,0001,833,0001,256,0001,396,00012,862,0001,350,000
       Accounts payable 
8,877,000
8,870,000
6,679,000
14,654,000
8,310,000
15,587,000
10,050,000
17,788,000
20,106,000
25,606,000
13,006,000
29,759,000
24,079,000
28,846,000
28,846,00024,079,00029,759,00013,006,00025,606,00020,106,00017,788,00010,050,00015,587,0008,310,00014,654,0006,679,0008,870,0008,877,000
       Other Current Liabilities 
19,239,000
21,784,000
24,117,000
24,014,000
27,972,000
26,509,000
26,642,000
24,066,000
28,693,000
29,977,000
33,535,000
32,300,000
35,118,000
45,524,000
45,524,00035,118,00032,300,00033,535,00029,977,00028,693,00024,066,00026,642,00026,509,00027,972,00024,014,00024,117,00021,784,00019,239,000
   > Long-term Liabilities 
19,644,000
24,246,000
34,984,000
34,821,000
35,899,000
36,831,000
38,190,000
33,662,000
34,558,000
38,270,000
34,404,000
68,952,000
68,561,000
104,781,000
104,781,00068,561,00068,952,00034,404,00038,270,00034,558,00033,662,00038,190,00036,831,00035,899,00034,821,00034,984,00024,246,00019,644,000
       Long term Debt 
12,398,000
9,654,000
24,084,000
24,178,000
24,136,000
20,775,000
24,267,000
19,415,000
19,924,000
15,976,000
16,764,000
51,608,000
51,452,000
84,246,000
84,246,00051,452,00051,608,00016,764,00015,976,00019,924,00019,415,00024,267,00020,775,00024,136,00024,178,00024,084,0009,654,00012,398,000
       Capital Lease Obligations Min Short Term Debt
0
4,129,000
0
0
0
4,529,000
0
0
0
5,726,000
0
0
0
6,766,000
6,766,0000005,726,0000004,529,0000004,129,0000
       Long-term Liabilities Other 
0
360,000
257,000
167,000
240,000
100,000
322,000
193,000
199,000
189,000
15,000
16,000
16,000
23,000
23,00016,00016,00015,000189,000199,000193,000322,000100,000240,000167,000257,000360,0000
> Total Stockholder Equity
66,112,000
70,746,000
66,550,000
74,452,000
76,680,000
83,486,000
79,874,000
90,473,000
92,991,000
106,561,000
98,911,000
112,522,000
120,522,000
143,486,000
143,486,000120,522,000112,522,00098,911,000106,561,00092,991,00090,473,00079,874,00083,486,00076,680,00074,452,00066,550,00070,746,00066,112,000
   Common Stock00000000000000
   Retained Earnings 
67,914,000
72,004,000
66,612,000
73,166,000
73,673,000
80,587,000
77,070,000
88,118,000
91,735,000
104,839,000
99,050,000
112,150,000
121,670,000
144,448,000
144,448,000121,670,000112,150,00099,050,000104,839,00091,735,00088,118,00077,070,00080,587,00073,673,00073,166,00066,612,00072,004,00067,914,000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 00000000000000



6.4. Balance Sheets

Currency in DKK. All numbers in thousands.




6.5. Cash Flows

Currency in DKK. All numbers in thousands.




6.6. Income Statements

Currency in DKK. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in DKK. All numbers in thousands.

Gross Profit (+$)
totalRevenue290,403,000
Cost of Revenue-44,522,000
Gross Profit245,881,000245,881,000
 
Operating Income (+$)
Gross Profit245,881,000
Operating Expense-162,064,000
Operating Income128,339,00083,817,000
 
Operating Expense (+$)
Research Development48,062,000
Selling General Administrative67,377,000
Selling And Marketing Expenses0
Operating Expense162,064,000115,439,000
 
Net Interest Income (+$)
Interest Income1,838,000
Interest Expense-1,640,000
Other Finance Cost-289,000
Net Interest Income-91,000
 
Pretax Income (+$)
Operating Income128,339,000
Net Interest Income-91,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)127,191,000129,396,000
EBIT - interestExpense = -1,640,000
100,988,000
102,628,000
Interest Expense1,640,000
Earnings Before Interest and Taxes (EBIT)0128,831,000
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax127,191,000
Tax Provision-26,203,000
Net Income From Continuing Ops100,988,000100,988,000
Net Income100,988,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-1,057,00091,000
 

Technical Analysis of Novo Nordisk A/S
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Novo Nordisk A/S. The general trend of Novo Nordisk A/S is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Novo Nordisk A/S's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Novo Nordisk A/S.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 88.80 < 90.40 < 92.89.

The bearish price targets are: 74.40 > 73.48 > 70.00.

Tweet this
Novo Nordisk A/S Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Novo Nordisk A/S. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Novo Nordisk A/S Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Moving Average Convergence/Divergence (MACD) ChartNovo Nordisk A/S Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Novo Nordisk A/S. The current adx is .

Novo Nordisk A/S Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Novo Nordisk A/S.

Novo Nordisk A/S Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Relative Strength Index (RSI) ChartNovo Nordisk A/S Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Novo Nordisk A/S.

Novo Nordisk A/S Daily Stochastic Oscillator ChartNovo Nordisk A/S Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Commodity Channel Index (CCI) ChartNovo Nordisk A/S Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Chande Momentum Oscillator (CMO) ChartNovo Nordisk A/S Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Novo Nordisk A/S.

Novo Nordisk A/S Daily Williams %R ChartNovo Nordisk A/S Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Novo Nordisk A/S.

Novo Nordisk A/S Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Average True Range (ATR) ChartNovo Nordisk A/S Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Novo Nordisk A/S.

Novo Nordisk A/S Daily On-Balance Volume (OBV) ChartNovo Nordisk A/S Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Novo Nordisk A/S.

Novo Nordisk A/S Daily Money Flow Index (MFI) ChartNovo Nordisk A/S Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Novo Nordisk A/S.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.

6.3. Candlestick Patterns

Novo Nordisk A/S Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Novo Nordisk A/S based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose80.400
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Novo Nordisk A/S with someone you think should read this too:
  • Are you bullish or bearish on Novo Nordisk A/S? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Novo Nordisk A/S? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Novo Nordisk A/S

I send you an email if I find something interesting about Novo Nordisk A/S.


Comments

How you think about this?

Leave a comment

Stay informed about Novo Nordisk A/S.

Receive notifications about Novo Nordisk A/S in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.